|Bid||0.0000 x 21500|
|Ask||0.0000 x 3200|
|Day's Range||1.2900 - 1.3600|
|52 Week Range||0.8500 - 4.9900|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.50|
At Insider Monkey, we pore over the filings of nearly 866 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of March 31st. In this […]
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Tyme Technologies, Inc. (Nasdaq:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today reported its conclusions from its recently conducted comprehensive strategic review and its fourth quarter and fiscal year 2021 financial results.